FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms
Cardiotoxicity remains a major limiting factor in the clinical implementation of anthracycline chemotherapy. Though the etiology of doxorubicin-dependent heart damage has yet to be fully elucidated, the ability of doxorubicin to damage DNA and trigger oxidative stress have been heavily implicated in...
Saved in:
| Main Authors: | Manish Kumar, Abhishek Singh Sengar, Anushree Lye, Pranesh Kumar, Sukhes Mukherjee, Dinesh Kumar, Priyadip Das, Suvro Chatterjee, Adele Stewart, Biswanath Maity |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-03-01
|
| Series: | Redox Biology |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2213231725000400 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Corrigendum to “FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms” [Redox Biol. 80 (2025) 103527]
by: Manish Kumar, et al.
Published: (2025-09-01) -
Cardiotoxicity in chemotherapeutic agents
by: Vitorino Modesto dos Santos, et al.
Published: (2021-03-01) -
Cardiotoxic effects of chemotherapeutical treatment in oncological patient
by: D. P. Kotova, et al.
Published: (2019-04-01) -
MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
by: G. E. Gendlin, et al.
Published: (2017-03-01) -
FNDC5/irisin-enriched sEVs conjugated with bone-targeting aptamer alleviate osteoporosis: a potential alternative to exercise
by: Min-Zhi Mao, et al.
Published: (2025-07-01)